Morgan Stanley (NYSE:MS) analyst Drew Ranieri maintained a Buy rating on Stryker Corporation (NYSE:SYK) on Friday, setting a price target of $305, which is approximately 17.44% above the present share price of $259.7.
Ranieri expects Stryker Corporation to post earnings per share (EPS) of $1.17 for the fourth quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in Stryker, with an average price target of $287.57.
The analysts price targets range from a high of $302 to a low of $250.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $4.16 billion and a net profit of $590 million. The company's market cap is $97.97 billion.
According to TipRanks.com, Morgan Stanley analyst Drew Ranieri is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.9% and a 40.00% success rate.
Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.